- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04739631
Efficacy of Acupuncture on Chemotherapy-Induced Peripheral Neuropathy
Efficacy of Acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Phase III, Randomized, Sham-controlled Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fang-Pey Chen, Ph.D
- Phone Number: 886-2-28757453
- Email: fpchen@vghtpe.gov.tw
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- Taipei Veterans General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
The study will enroll patients with a symptom of peripheral neuropathy, including paresthesia, numbness, glove-and-stocking sensory loss distribution or pain in four limbs, and meet the following inclusion criteria:
- All adult cancer patients (Age≧20-year-old) who received chemotherapy regimens, including adjuvant and neoadjuvant therapy
- Stage I-III cancer patients
- Completed chemotherapy regimens more than3 months, including Taxanes (paclitaxel or docetaxel), platinum (cisplatin, oxaliplatin, carboplatin)
- Baseline von Frey Monofilament test (Target force at hand) ≧ 0.07gms
- Baseline von Frey Monofilament test (Target force at foot) ≧ 0.4gms
- Eastern Cooperative Oncology Group (ECOG) performance status ≦3
- Grading of peripheral sensory neuropathy in National Cancer Institute- common terminology criteria for adverse events,v5.0 (NCI-CTCAE5) ≧1
- Patients were restricted acupuncture treatment for one month before recruitment
- Written patient informed consent
Exclusion criteria:
Participants with any of the following conditions will be excluded:
- Uncontrolled Diabetic Mellitus, HbA1c≧7% is inappropriate[19].
- Diabetic neuropathy diagnosed before receiving chemotherapy
- Neuropathy from any type of nerve compression (e.g., carpal/tarsal tunnel syndrome, radiculopathy, spinal stenosis, brachial plexopathy)
- Concomitant with duloxetine, or another analgesia, including Pregabalin, Venlafaxine, Minocycline, Topical gel, Oxycodone, Naloxone, Cannabinoids, and Angiotensin II type 2 receptor antagonist
- Severe hemorrhagic coagulopathy or bleeding tendency
- Unstable cardiovascular disease
- Severe skin lesions around the treatment sites The researchers will exclude any participants considered to be inappropriate for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: sham-controlled group
The sham acupuncture group will be performed by superficial needling with less than 4mm depth.
The needling location is about 0.5 cm away from the acupoints.
Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
|
The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
|
Experimental: acupuncture group
The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks).
Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture.The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3 mm×30 mm.
The depth of needling varied based on the patient's body sizes.
After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
|
use disposable sterile needles to insert to the acupuncture point
|
No Intervention: waitlist-control group
As an waitlist-control group, no acupuncture will be performed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FACT-Neurotoxicity subscale(NtxS)
Time Frame: It will be assessed before the first intervention in the first week, after the 12th intervention in the 4th week , after the 20th intervention in the 8th week, and the follow-up assessment in the end of the 12th week. Each intervention is one day.
|
The primary outcome will be the change FACT-Neurotoxicity subscale(NtxS) from baseline to 20 sessions at 8th weeks.
The neurotoxicity subscale from the FACT/GOG-NTX-13(version 4) contains 13 items assessing numbness, tingling, and discomfort in the hands or feet, difficulty hearing, tinnitus, joint pain or muscle cramps, weakness, or trouble walking, buttoning buttons, or feeling small shapes when placed in the hand.
Items are scored from 0-4 (0 = not at all; 4 = very much) and summed (total score range = 0-52).
Since no published data are defining a cut-point for determining a clinically important change in the FACT/GOG Ntx score, we defined a 4 point change as a clinically meaningful improvement in patient-reported CIPN-related neurotoxicity outcome .
The authorized translated traditional Chinese version will be purchased in this study.
|
It will be assessed before the first intervention in the first week, after the 12th intervention in the 4th week , after the 20th intervention in the 8th week, and the follow-up assessment in the end of the 12th week. Each intervention is one day.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of BPI-SF
Time Frame: It will be assessed before the first intervention in the first week, after the 12th intervention in the 4th week , after the 20th intervention in the 8th week, and the follow-up assessment in the end of the 12th week. Each intervention is one day.
|
Our secondary outcome will be the change of average pain severity in BPI-SF from baseline to 20 sessions at 8th weeks.
BPI-SF is an instrument used to evaluate the severity of pain, including neuropathic pain and the interference on the patients' daily functioning.
Items are scored from 0 to 10 (0= no pain; 10= pain as bad as you can imagine).
Since not all the patients feel pain in their daily life, we selected the participants who have average pain severity more than 4 points at baseline assessment into the final analysis.
The authorized translated traditional Chinese version will be purchased in this study.
|
It will be assessed before the first intervention in the first week, after the 12th intervention in the 4th week , after the 20th intervention in the 8th week, and the follow-up assessment in the end of the 12th week. Each intervention is one day.
|
The quantitative sensation of touch detection
Time Frame: It will be assessed before the first intervention in the first week, after the 20th intervention in the 8th week, and the follow-up assessment in the end of the 12th week. Each intervention is one day.
|
The quantitative sensation of touch detection was used to test sensory levels and obtain objective data on the status of diminishing or returning sensibility. Touch detection was measured using von Frey monofilaments (Semmes-Weinstein Von Frey Aesthesiometer, Stoelting Co. 620 Wheat Lane, Wood Dale, IL, USA), with weights from 0.008 g to 300 g at 8 points. The measuring sites including the bases of the sole, tips of the big toe, palmar sides of hands, and the fingertips of the middle finger. The well-known up-down method applied to measure touch-detection thresholds. It will be assessed before the first intervention in the first week, after the 20th intervention in the 8th week, and the follow-up assessment in the end of the 12th week. Each intervention is one day. Each von-Frey test or questionnaire will be performed within seven days from each time point. |
It will be assessed before the first intervention in the first week, after the 20th intervention in the 8th week, and the follow-up assessment in the end of the 12th week. Each intervention is one day.
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-09-005C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-Induced Peripheral Neuropathy (CIPN)
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Leiden University Medical Center; Reinier de GraafRecruitingChemotherapy-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Qutenza | DuloxetineNetherlands
-
Uppsala UniversityUnknownChemotherapy Induced Peripheral Neuropathy (CIPN)Sweden
-
Peking University People's HospitalEnrolling by invitationChemotherapy-induced Peripheral Neuropathy | CIPNChina
-
ARCIM Institute Academic Research in Complementary...RecruitingChemotherapy-induced Peripheral Neuropathy (CIPN)Germany
-
Sonnet BioTherapeuticsTerminatedChemotherapy-induced Peripheral Neuropathy (CIPN)Australia
-
Egetis TherapeuticsCompletedChemotherapy Induced Peripheral Neuropathy (CIPN)United States
-
China Medical University HospitalTaipei Veterans General Hospital, TaiwanNot yet recruitingChemotherapy-Induced Peripheral Neuropathy (CIPN)Taiwan
-
National University Hospital, SingaporeCompletedChemotherapy-induced Peripheral Neuropathy (CIPN)
-
Wake Forest University Health SciencesHonorHealth Research InstituteRecruitingCIPN - Chemotherapy-Induced Peripheral NeuropathyUnited States
-
Johns Hopkins UniversityTerminatedChemotherapy-induced Peripheral Neuropathy (CIPN)United States
Clinical Trials on acupuncture
-
Federal University of São PauloCompleted
-
University of ZurichCharite University, Berlin, Germany; First Teaching Hospital of Tianjin University...CompletedExperimental Dental PainSwitzerland
-
University of SkövdeCompleted
-
National Research Centre of Complementary and Alternative...Norwegian Acupuncture CollegeUnknown
-
Chengdu University of Traditional Chinese MedicineChongqing Medical University; Hunan University of Traditional Chinese MedicineCompletedFunctional Dyspepsia | Postprandial Distress SyndromeChina
-
University of MichiganMassachusetts General Hospital; National Center for Complementary and Integrative...Completed
-
Chang Gung Memorial HospitalRecruitingIntracranial HemorrhagesTaiwan
-
University Medicine GreifswaldRecruitingGagging During Transesophageal EchocardiographyGermany
-
Huazhong University of Science and TechnologyThe University of Hong Kong; Heilongjiang University of Chinese Medicine; Hubei...CompletedPolycystic Ovary SyndromeChina
-
China Medical University HospitalNot yet recruiting